Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Reduction Strategies in Oral Opioid Dependence Subsequent to Pain Management
NCT00218101Phase 2Completed
- Sponsor
- National Institute on Drug Abuse
- Start
- May 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of buprenorphine in opioid use disorder (OUD) (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Substance use, Medication compliance and 1 more. Started May 2004; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00218101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00218101.